ДЖЕЙН Ракеш Кумар (US),БОУЧЕР Увес (US),ЧАУХАН Викаш Пал Шинг (US),ДИОП-ФРИМПОНГ Бенджамин (US),КРЕЙН Стефан (US),КРЕЙН Алан Л. (US),ЛАНГЕР Роберт Самюэль (US)
申请号：
RU2013127625/15
公开号：
RU2013127625A
申请日:
2011.11.18
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method for improving the delivery or efficacy of cancer therapy in a patient, comprising: identifying a patient in need of an antihypertensive and / or collagen modifying agent (ANSM) based on a need for improved delivery or enhancing the effectiveness of cancer therapy, and (a), or (b) either one or the other: (a) administering ANSM to a patient, or (b) administering cancer therapy, wherein the ANSM is administered in a dose sufficient to improve delivery or increase the effectiveness of cancer therapy. 2. A method for treating or preventing cancer in a patient, comprising: identifying a patient in need of an antihypertensive and / or collagen modifying agent (ANSM) based on a need to improve delivery and / or increase the effectiveness of cancer therapy, and (a) or (b) or both: (a) administering an ANSM to a patient； or (b) administering cancer therapy, wherein the ANSM is administered in a dose sufficient to treat or prevent cancer. 3. The method according to claim 1 or 2, comprising one or more of the following: a) administering ANSM, using cancer therapy, or both in the form of particles having a hydrodynamic diameter greater than 1, 5, 10, 15, 20, 25, 30, 35, 45, 50, 75, 100, 150, 200 nm, but less than 300 nm, b) the patient was not given a dose of ANSM for 5, 10, 30, 60 or 100 days after diagnosis of cancer or dosing of ANSM, c) patient does not suffer from hypertension or suffered from hypertension before the administration of ANSM, d) ANSM is administered for at least one, two, three or five days； or one, two, three, four, five or more weeks before starting cancer therapy, e) ANSM is administered for at least one, two, three or five days； or one, two, three, four, five or more weeks before starting treatment1. Способ улучшения доставки или повышения эффективности терапии рака у пациента, включающий:идентификацию пациента, нуждающегося в получении антигипертензивного и/или модифицирующего коллаген средства (АНСМ), на основании потребности в улучшении до
